Capricor Therapeutics
Los Angeles
About Capricor Therapeutics
Capricor Therapeutics is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of cell and exosome-based therapeutics for the treatment and prevention of diseases. Its CAP-1002 is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and COVID-19. The company was founded in 2005 and is headquartered in Los Angeles, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $329.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: nasdaq:CAPR
- Website: capricor.com
- Phone: (310) 358-3200
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/capricor-therapeutics-35112 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.